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Abstract
Spinocerebellar ataxias (SCAs) are a genetically heterogeneous group of cerebellar degenerative
disorders, characterized by progressive gait unsteadiness, hand incoordination, and dysarthria.
Ataxia type 1 (SCA1) is caused by the expansion of a CAG trinucleotide repeat in the SCA1 gene
resulting in the atypical extension of a polyglutamine (polyQ) tract within the ataxin-1 protein. Our
main objective was to investigate the mitochondrial oxidative metabolism in the cerebellum of
transgenic SCA1 mice. SCA1 transgenic mice develop clinical features in the early life stages
(around 5 weeks of age) presenting pathological cerebellar signs with concomitant progressive Pur-
kinje neuron atrophy and relatively little cell loss; this evidence suggests that the SCA1 phenotype
is not the result of cell death per se, but a possible effect of cellular dysfunction that occurs before
neuronal demise. We studied the mitochondrial oxidative metabolism in cerebellar cells from both
homozygous and heterozygous transgenic SCA1 mice, aged 2 and 6 months. Histochemical exami-
nation showed a cytochrome-c-oxidase (COX) deficiency in the Purkinje cells (PCs) of both
heterozygous and homozygous mice, the oxidative defect being more prominent in older mice, in
which the percentage of COX-deficient PC was up to 30%. Using a laser-microdissector, we eval-
uated the mitochondrial DNA (mtDNA) content on selectively isolated COX-competent and COX-
deficient PC by quantitative Polymerase Chain Reaction and we found mtDNA depletion in those
with oxidative dysfunction. In conclusion, the selective oxidative metabolism defect observed in
neuronal PC expressing mutant ataxin occurs as early as 8 weeks of age thus representing an early
step in the PC degeneration process in SCA1 disease.
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1 | INTRODUCTION
Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant inher-
ited neurodegenerative disease characterized by neurodegeneration in
multiple central nervous system (CNS) regions, including spinal cord,
brain stem, and cerebellum (Zoghbi & Orr, 1995).
The disease is associated with an unstable trinucleotide CAG
repeat expansion in the open reading frame of the ataxin-1 gene. This
specific CAG repeat expansion leads to the expression of an expanded
polyglutamine (polyQ) tract in the mutant ataxin-1 protein (ATXN1),
thereby acquiring a toxic gain-of-function property (Orr, 2012; Zoghbi,
1995; Zoghbi & Orr, 2009).
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Also, it was showed that the overexpression of the normal form of
ataxin-1, produces similar toxic effects (Fernandez-Funez et al., 2000),
suggesting that an activity of ATXN1 in excess is sufficient to cause
neuronal dysfunction.
Although genetic analyses, epidemiological data, neuropathological
investigations are providing important new insights into the etiology of
spinocerebellar ataxias (SCAs), the pathological mechanism of these
diseases is still poorly understood (Duenas, Goold, & Giunti, 2006), and
the toxic mechanisms by which the ataxin-1 protein induces neuronal
Purkinje cells (PCs) death has been investigated.
Different mouse models have been generated to study the cere-
bellar degeneration associated with SCA1 (Burright et al., 1995;
Watase et al., 2002).
The transgenic animal model, generated by Burright et al. (1995) at
the University of Minnesota, expresses the full length human SCA1
cDNA with 82 CAG repeats controlled by a specific Purkinje cell
protein-2 (Pcp2) promoter (Oberdick, Smeyne, Mann, Zackson, &
Morgan, 1990; Vandaele et al., 1991).
This mouse model develops a progressive motor disorder starting
in the early stages of life (around 5 weeks of age), before the appear-
ance of any alteration of cerebellar morphology. Pathological abnormal-
ities of PC, in the form of a shrunken dendritic tree and migration of
the cell body into the molecular layer, become clearly visible by 12
weeks of age, along with an initial decline in PC number. A significant
PC loss (approximately a third) occurs by 24 weeks of age. Interestingly,
some authors suggested that neuronal dysfunction rather than neuro-
nal loss is central to the disease process (Clark et al., 1997).
Mitochondrial dysfunction and oxidative damage are prominent
features of various neurodegenerative diseases such as Amyotrophic
Lateral Sclerosis, Spinal Muscular Atrophy, Alzheimer Disease, Parkin-
son’s disease, Huntington Disease, hereditary spastic paraplegia, Frie-
dreich’s ataxia, and Charcot-Marie-Tooth disease (Allen, Duffy, Shaw, &
Grierson, 2015; DiMauro & Schon, 2008; Ripolone et al., 2015).
Neurons are particularly sensitive to changes in mitochondrial func-
tion as they are extremely energy-dependent (Gironi et al., 2004; Kann &
Kovacs, 2007). Being the apoptotic pathways related to mitochondrial
dysfunction (Clark et al., 1997; Duenas et al., 2006), some evidences have
shown that in some forms of cell damage occurring in polyglutamine-
diseases the observed phenotype may be related to apoptotic cell death.
Herein, searching for the possible explanation of cerebellar dys-
function, we tried to gain insight into the pathogenesis of this disease
studying the mitochondrial oxidative metabolism in vivo in the cerebel-
lum of transgenic SCA1 mice. In this view, considering the onset of the
clinical symptoms, we decided to study mice at 2 months of age, soon
after the beginning of symptoms, and then at the age of 6 months
when both clinical symptoms and cerebellar alteration are clearly
manifest.
We compared the histopathological changes, the presence of apo-
ptosis, and the mitochondrial oxidative enzymatic activity in these
mice. Also, using a laser-microdissector, we evaluated the mitochon-
drial DNA (mtDNA) content on selectively isolated COX-competent
and COX-deficient PC by quantitative Polymerase Chain Reaction
(PCR).
2 | MATERIALS AND METHODS
2.1 | Animals
All experiments in this study were performed on SCA1 transgenic
mice and control mice generated by Dr. H. Orr at the University of
Minnesota (Burright et al., 1995) and kindly supplied by Dr. Pan-
dolfo, Universite Libre de Bruxelles, Bruxelles (Belgium). A colony
of heterozygous and homozygous SCA1 B05 82Q mice was kept in
our animal facility, animals being maintained at 228C618C on a 12
hr light/12 hr dark schedule, with free access to food and water.
All protocols for animal care, handling, and euthanasia were per-
formed in accordance with the guidelines for the care and use of
Laboratory Animals promulgated by the Italian Minister of Health,
DL 27 January 1992, No. 116 and the EU directive 86/609/CEE.
Mice were sacrificed with cervical dislocation, through occipital
access brain was taken up to brainstem. It was frozen with quick
immersion in liquid nitrogen-cooled isopentane and then in liquid
nitrogen. Frozen tissues were mounted on the ventral side and cut
in cross sections. Thirty-six mice (twenty males and sixteen
females) were sacrificed and studied, namely six heterozygous and
six homozygous SCA1 transgenic 2-month old mice, six heterozy-
gous and six homozygous SCA1 transgenic 6-month old mice, and
twelve control mice (six 2 months old, six 6 months old).
2.2 | Histopathological and biochemical analysis
Histological staining and histochemical reactions both for detection of
morphological CNS alterations and mitochondrial enzymatic defects
were performed on 8-lm thick transverse cryostat sections from
mouse whole brains prepared as described (Ripolone et al., 2015;
Sciacco & Bonilla, 1996).
Morphological evidence for apoptosis was tested using terminal
deoxynucleotidyl transferase-mediated dUTP nick end labeling
(TUNEL). The TUNEL method was set up following the manufacturer’s
instructions (In Situ Cell Death Detection Kit, Roche, Mannheim,
Germany) and according to our previous studies (Sciacco et al., 2001).
Significance
This work uses an animal model to try to understand the pathogenesis
of a progressive human disease (spinocerebellar ataxia type 1, SCA1)
characterized by progressive gait unsteadiness, hand incoordination,
and dysarthria and transmitted as an autosomal dominant disorder. In
particular, we focused our studies on the progressive dysfunction of
Purkinje cells (PCs) and we hypothesize that a mitochondrial oxidative
defect represents an early pathogenetic step of the degeneration
process. Understanding the pathogenesis is extremely important
because it can help the development of therapeutic strategies aiming
at preserving PCs, delaying disease onset, and slowing its progression.
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TUNEL sections were compared with serial methylene blue stained
sections.
For immunohistochemistry, cryostatic cerebellum sections (8 lm
thick) were postfixed in 4% Paraformaldehyde (Sigma-Aldrich, S.r.l.
Milan, Italy), blocked in 3% Bovine Serum Albumin (Sigma-Aldrich), and
incubated with primary and secondary antibodies at the appropriate
dilution. Primary antibodies were anti-calbindin D-28K polyclonal anti-
body (diluition: 1:500, 2d-Chemicon, Thermo Fisher Scientific, Milan,
Italy), anti-OxPhos Complex IV subunit I monoclonal antibody (diluition
1:500, ON Invitrogen), anti-TOMM20 monoclonal antibody (diluition
1:250 ON Abcam, Cambridge, United Kingdom). Alexa 488- or Alexa
568-conjugated IgGs were used as secondary antibodies (Invitrogen,
Carlsbad, CA).
Biochemical analyses were performed on the 750g superna-
tants obtained from brains and cerebellum homogenates. Enzyme
activities of respiratory chain complexes I, II, III, IV (cytochrome-c-
oxidase, COX) and of citrate synthase (CS) were measured spec-
trophotometrically and the specific activities of each complex
were normalized to CS, an indicator of the number of mitochon-
dria (Bresolin et al., 1987).
2.3 | Electron microscopy
For ultrastructural examination, a small part of cerebellum samples was
fixed in 2.5% glutaraldehyde (pH 7.4), postfixed in 2% osmium tetrox-
ide and then, after dehydration in a graded series of ethanol, embedded
in Spurr’s resin. Finally, ultrathin sections were stained with lead citrate
and uranyl acetate and examinated with Zeiss EM109 transmission
electron microscope (Ripolone et al., 2015).
For immunoultrastructural evidence of COX enzymatic activity,
small samples of cerebellum from 2- and 6-month old mice were incu-
bated in 0.1M phosphate buffer, pH 7.4, 5 mM 3,30-Diaminobenzidine
tetrahydrochloride, 0.25M cytochrome c, 0.2M sucrose, for 1 hr at
378C. After two washes in 0.1M phosphate buffer, pH 7.4, samples
were fixed in 2.5% glutaraldehyde (pH 7.4) and processed according to
the standard protocol, ultrathin sections were not stained with lead
citrate and uranyl acetate before the examination (Bonilla, Schotland,
DiMauro, & Aldover, 1975).
2.4 | Quantitative analysis of COX deficit in PCs
Morphometric evaluation of COX-deficient and COX-competent PC
was made on 12-lm-thick transverse cerebellar sections. Each section
was entirely acquired at 100X with a Leica microscope equipped with a
video-camera (Leica DCF 320) by using dedicated imaging software.
Pictures were analyzed using the image analyzer software IM50 (Leica
Image Manager IM50). Three different blinded operators counted
COX-deficient and COX-positive PC in each picture following the pro-
tocol by Peverelli et al. (2015). We analyzed five non-transgenic (non-
TG) samples, five heterozygous 2- and 6-month old mice (totally 10
samples) and five homozygous 2- and 6-month old mice (totally 10
samples).
2.5 | Laser-capture microdissection
and mtDNA analysis
Frozen cryostat sections (16 lm) were collected on 2-mm thick pen mem-
brane slides, stained for COX activity detection, and air-dried. Individual
COX-competent and -deficient PC were microdissected by using a Leica
Laser Microdissection System (Leica AS-LMD) (Edwards, 2007).
PC from four 6-month old SCA1 homozygous and three control
mice were dissected from each section and collected in groups of 300
cells per type into single test tubes. We also collected granular cells
(GCs) from all dissected mice as internal control for both oxidative
damage and mtDNA content.
DNA was extracted by laser-microdissected cells using the
QIAamp DNA Micro Kit (QIAGEN, Italia, Milan, Italy).
Mouse mtDNA was quantified by Real time PCR using an ABI
7500 detection system as previously described (Spinazzola et al.,
2006). The primers and probe for murine mt-Co1, mt-Co3, mt-Nd4
genes (mtDNA), and for Tfrc and 18S ribosomal RNA gene (nDNA)
were used for that purpose and are available upon request. All the
determinations were carried out in triplicate using 5 ll of cell lysates as
a template. Nuclear-DNA normalized mtDNA levels were expressed in
terms of relative quantification (RQ) values considering as reference
(RQ51) the amount of mtDNA detected in PC from a control mouse
using the Double Delta Cycle Threshold (Ct) Value (DDCt) method.
Briefly, mtDNA levels are obtained by applying this formula: 2 2
[(CtmtDNATARGET_SCA1 2 CtnDNATARGET_SCA1) 2 (CtmtDNATARGET_CTRL 2
CtnDNATARGET_CTRL)].
Analysis of mtDNA point mutation is described in Supporting
Information.
2.6 | Statistical analyses
Data for all parameters measured were expressed as group means6
standard deviation. There was no evidence for significant deviations
from normal distribution (p> .05, Shapiro–Wilk test). Group data were
analyzed using one-way analysis of variance (ANOVA) followed by post
hoc Tukey tests for multiple comparisons. Comparisons of mtDNA lev-
els in GCs, brain, and cerebellum tissues between SCA1 and control
mice were made using an unpaired t test (with Bonferroni correction
for multiple comparisons, as appropriate). The level of significance was
set at p< .05. Statistical analyses were conducted using Prism 5.0
(GraphPad Sofware, Inc.) and STATA version 13.0 (StataCorp, College
Station, TX).
3 | RESULTS
3.1 | PC mitochondrial oxidative defect in SCA1 mice,
histochemical and ultrastructural examination
To investigate the mitochondrial defect in SCA1 mice, we investigated
histological examination and histochemical reactions for COX on serial
cryostat sections on both homozygous and heterozygous 2 and 6 months
old mice, and compared with those from control animals (Figure 1a–h).
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General morphological analyses were in line with previous data
(Burright et al., 1995; Clark et al., 1997) indeed SCA1 transgenic mice
present clinical features of cerebellar dysfunction.
In detail, we observed a mild loss of the PC population in the cere-
bellar cortex of both heterozygous and homozygous 2 months old
mice. The loss of PC became more evident in both heterozygous and
homozygous 6 months old mice, in which we observed some PC in het-
erotopic positions within the molecular layer and, occasionally, in the
granular layer.
To evaluate the potential role of apoptosis in the degeneration of
PCs, we performed Tunel experiments, but we found apoptosis in very
few PC in both heterozygous and homozygous 2 and 6 months old
mice. We therefore conclude that apoptosis does not seem to be
involved in PC degeneration (Supporting Information Figure 1).
The histochemical examination showed similar amounts of COX-
deficient PC in both heterozygous and homozygous mice, although, the
oxidative defect was more pronounced in older (6 months old) mice
(Figure 1).
To precisely assess the morphologically observed oxidative
defect, we performed a quantitative analysis of the COX-deficient
and COX-competent PC number. In addition to correctly recognize
COX deficiency in PC, we performed co-immunohistochemistry of
the respiratory chain Complex IV (subunit I) and calbindin, a marker
of Purkinje neurons, by using appropriate antibodies (Figure 1i–l).
We found that the percentage of COX-deficient PC over the total
number of PC was significantly different across experimental condi-
tions (F4,20565.45, p< .001). In particular, it was substantially
increased in both homozygous and heterozygous animals aged 2
and 6 months compared with controls (12%, p< .001). Further-
more, a higher number of COX-deficient PC was observed in 6-
month old mice compared with younger ones (30%, p< .001) (Sup-
porting Information Figure 2).
FIGURE 1 Light microscopy: histology-histochemistry-immunohistochemistry. Serial sections showing cerebellum from a non-TG mouse (a, b), a
2-month old spinocerebellar ataxia type 1 (SCA1)-homozygous mouse (c, d), and a 6-month old SCA1-homozygous mouse (e–h). The type of stain-
ing is indicated on each photo. Cytochrome-c-oxidase (COX)-positive and COX-negative cells are indicated by black and white circles, respectively.
Co-immunostaining with both anti-COX1 subunit and anti-calbindin antibodies is shown on Purkinje neurons from a non-TG mouse (i, k) and from
a 6-month old SCA1-homozygous mouse (j, l). COX-deficient neurons are marked with asterisks. Scale bar: 15 mm
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Finally, ultrastructural immunostaining for COX activity confirmed
that the lack of enzymatic activity was confined to PC as shown in Fig-
ure 2. Indeed, many mitochondria membranes were not electron dense
in SCA1 mice, while they are clearly electron dense in both controls
and in granular cerebellar cells from SCA mice (Figure 2).
Taken together, our experimental evidences show a selective COX
deficiency in a significant amount of PC from genetically affected mice.
3.2 | Biochemical analysis
Enzymatic assay of respiratory chain activities was performed on cere-
bellar tissue of five heterozygous and five homozygous SCA1 trans-
genic mice aged 6 months and in five controls. The values are
presented in Table 1. The activities of cII1 III and cIV complexes, as
well as the activity of CS, in both groups of SCA1 transgenic mice dif-
fered significantly from controls (Table 1).
There was a significant increase in cII/CS activity in heterozy-
gous animals compared with controls. cII/CS activity was also
increased in homozygous mice but not significantly. A trend toward
a higher cI1 III activity in transgenic mice was observed. No signifi-
cant differences were found between SCA1 heterozygous and
homozygous mice (Table 1).
3.3 | mtDNA molecular analysis in SCA1
mice cerebellum
3.3.1 | mtDNA point mutation analysis
Sequencing analysis revealed less than one point mutations per 10 kbp
in CytB region of mtDNA amplified from COX-positive and COX-
deficient PC. No mutations were detected in clones representative of
MT-COI and D-loop regions.
FIGURE 2 Electron microscopy: cytochrome-c-oxidase (COX) immunostaining in 6 months old control and spinocerebellar ataxia type 1
(SCA1)-homozygous mice. (a) Purkinje cell (PC) from a non-TG mouse without COX immunostaining. Scale bar: 2200 nm. (b) COX enzymatic
activity in non-TG PC. All mitochondria show COX activity (arrows). Scale bar: 1400 nm. (c) COX enzymatic activity in a PC from SCA1-
homozygous 6 months old mouse. COX-negative mitochondria are marked with an asterisk. Scale bar: 1600 nm. (d) COX enzymatic activity
in a PC from SCA1-homozygous 6 months old mouse. COX-positive mitochondria are marked with arrows. Scale bar: 1400 nm. (e) COX
enzymatic activity in SCA1-homozygous granular cell. All mitochondria show COX activity (arrows). Scale bar: 1400 nm. N5nucleus
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3.3.2 | mtDNA depletion
mtDNA content was assessed in laser-microdissected PC by quantita-
tive PCR determinations in a series of RQ experiments. Levels of
mtDNA in COX-deficient PC from SCA1 mice were significantly
decreased compared with COX-competent PC isolated from SCA1 and
control mice (Figure 3; Supporting Information Table 1). mtDNA con-
tent was not always homogenous in the analyzed mice. Nevertheless,
the ratio of mtDNA levels of isolated COX-deficient and COX-positive
PC showed a strong mtDNA depletion ranging from 54 to 89% in all
the mutant mice. Notably, these findings were limited to PC, as we
detected no difference in mtDNA content of GCs isolated from SCA1
and control mice (p> .05). We also quantified mtDNA in whole brain
and cerebellum tissues. Levels of brain-derived mtDNA were not signif-
icantly different between SCA1 and control mice (p> .05). Conversely,
mtDNA levels were significantly reduced in cerebella of SCA1 mice
(Supporting Information Figure 3). We suggest that the observed low
mtDNA content in PC of SCA1 mice is not a result of the reduction of
the amount of mitochondria, indeed immunofluorescence analysis of
the outer mitochondrial membrane protein TOMM20, a marker of
mitochondrial content, has a similar pattern of intensity in SCA1 and in
control mice (Supporting Information Figure 4C,D).
Also, standard electron microscopy examination confirmed the
presence of a normal amount of normally shaped and distributed PC
mitochondria in the cerebellum of both transgenic and control mice
(Supporting Information Figure 4A,B).
4 | DISCUSSION
SCA1 is a late-onset autosomal dominant neurodegenerative disorder
of the nervous system caused by the toxic effects triggered by an
expanded polyglutamine within ataxin-1 protein. The neuronal degen-
eration afflicts primarily the cerebellar PC and brainstem neurons, lead-
ing to the characteristic ataxic phenotype and bulbar dysfunction.
In SCA1 transgenic mice, the overexpression of mutant ataxin-1
results in a progressive ataxia and PC pathology is very similar to those
seen in SCA1 patients (Burright et al., 1995).
Interestingly, the pathology develops as a result of an early neuro-
nal dysfunction and atrophy, without neuronal loss (Clark et al., 1997),
making the model helpful to define the causes of PC dysfunction and
to study the disease pathogenesis.
Our main objective was to investigate the mitochondrial oxidative
activity in cerebellar cells of transgenic SCA1 mice trying to correlate
the dysfunction with the earliest histopathological changes and possi-
ble mtDNA defects.
In this regard, we studied both heterozygous and homozygous
SCA1 transgenic mice, aged 2 and 6 months, by histological and histo-
chemical techniques.
Our results showed a selective COX deficiency in several PC from
pathologic mice, COX activity being normal in all other cerebellar cells
and in control mice.
In particular, we detected similar amounts of COX-deficient PC in
both heterozygous and homozygous affected mice, the defect being
more evident in the older ones, in which the percentage of COX-
deficient PC was up to 30% (Figure 1; Supporting Information Figure
1). The fact that heterozygous and homozygous transgenic mice
express the oxidative defect at the same level indicates that the level
of accumulation of the ataxin-1 protein in heterozygous mice is enough
to determine the neuronal damage.
Similarly, the other SCA1 mouse model, SCA1 154Q/2Q (Watase
et al., 2002) and the transgenic mice for AFG3L2, the gene responsible
for autosomal dominant SCA28 (Di Bella et al., 2010), display cerebellar
TABLE 1 Mean (standard deviation) for respiratory chain activities in heterozygous and homozygous spinocerebellar ataxia type 1 transgenic
mice aged 6 months and in controls
Non-TG Hetero 6m Homo 6m p Value
a post hoc test
(n55) (n55) (n55) p Valuea Hetero 6m vs. Non-TG Homo 6m vs. Non-TG
cI/CS 10.22 (0.77) 8.73 (1.37) 10.51 (1.57) F2,1252.78,
p5 .102
ns ns
cII/CS 2.07 (0.48) 3.27 (0.312)** 2.60 (0.48) F2,1259.66,
p5 .003
.002 ns
cI1III/CS 5.95 (0.69) 8.00 (1.52) 8.21 (1.68) F2,1254.17,
p5 .042
ns ns
cII1III/CS 1.22 (0.15) 2.21 (0.41)** 2.73 (0.56)*** F2,12517.51,
p< .001
.006 <.001
cIV/CS 14.70 (2.65) 31.01 (8.40)** 36.16 (5.93)*** F2,12516.70,
p< .001
.003 <.001
CS 435.40 (23.21) 358.30 (46.52)** 330.20 (22.21)*** F2,12513.92,
p < .001
.007 <.001
Note. ns5 not significant; Non-TG5 non-transgenic. Values are expressed as mean6 standard deviations (pmol/min/mg), after normalization to citrate
synthase (CS). CS activity is normalized to protein content.
The bold values are statistically significant.
aOne-way analysis of variance with Tukey’s post hoc test.
**p< .01; ***p< .001 versus controls.
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mitochondrial dysfunction at histochemical and molecular level (Mal-
tecca et al., 2009; Stucki et al., 2016).
We also investigated the apoptotic phenomenon in PC degeneration,
indeed, as apoptosis is involved in response regulation to cellular damage,
it has been hypothesized that polyglutamine proteins activate the apopto-
tic machinery and that the cell loss is a central component of the disease
(Paulson, Bonini, & Roth, 2000). The apoptotic pathway had already been
studied in SCA1 transgenic mice aged 15 and 20 weeks, and the authors
had not found a significant number of TUNEL-positive PC (Shahbazian,
Orr, & Zoghbi, 2001). In agreement with these results, we only found few
apoptotic nuclei in cerebellum cells which prevented us from performing a
quantitative analysis (Supporting Information Figure 1).
The determination of COX activity by biochemical assay on
homogenates of the whole cerebellum did not reveal any defect in the
late disease stage, at 6 months of age. This result is largely explained
by the different nature of the methods used to evaluate COX activity.
The histochemistry allows to detect specific cell defects (affecting in
this case a subset of PC only), whereas the biochemical assay pools in
the same homogenate proteins of the entire cerebellum, therefore
masking a specific cell defect (DiMauro et al., 2006). Complex IV (COX)
FIGURE 3 Quantitative mitochondrial DNA (mtDNA) analysis: mtDNA content in cytochrome-c-oxidase (COX)-deficient Purkinje cell (PC)
and COX-competent PC isolated from spinocerebellar ataxia type 1 (SCA1) mice (n54) and control mice (n53). Cells were microdissected
using a Leica Laser Microdissection System (Leica AS-LMD) from frozen cryostat sections (16 lm) and collected in groups of 300 cells per
type into single test tubes. Nuclear-DNA normalized mtDNA levels were expressed in terms of relative quantification (RQ) values consider-
ing as reference (RQ51) the amount of mtDNA detected in PC from controls. The primers and probe for murine mt-Co1, mt-Co3, mt-Nd4
genes (mtDNA) and for Tfrc and 18S ribosomal RNA gene (nDNA) were used. The red horizontal line represents the mean and the error
bars represent the standard deviation. Significant differences are indicated. *p< .05; **p< .01; ***p< .001 (See Supporting Information
Table 1 for details)
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activity was also preserved at an earlier time point (2 months age).
However, in younger transgenic mice, we were able to detect a mild
reduction cII1 III activity as previously observed in presymptomatic
SCA1-mice (Sanchez, Balague, & Matilla-Due~nas, 2016).
To search for an explanation of the observed selective oxidative
defect, we studied the mtDNA content in both COX-deficient and
COX-competent PC from 6 months old homozygous and control mice
and in GC derived from SCA1 mice. To this purpose, we isolated and
collected single, histochemically identified COX-positive/competent
and COX-deficient PC, using a laser microdissector. After excluding an
increased rate of point mutations in mtDNA, we observed a global
reduction of mtDNA content in PC lacking COX activity while COX-
competent PC and GC were spared. We suggest that the observed low
mtDNA content in PC of SCA1 mice is not a result of the reduction of
the amount of mitochondria by comparing SCA1 and control mice in
both ultrastructural images and TOMM20 intensity (Supporting Infor-
mation Figure 4).
This distribution resembles the coexistence of COX-positive and
COX-deficient fibers found in skeletal muscle tissue from individuals
affected with genetically determined mitochondrial disorders in which
even a little percentage of COX deficient fibers can lead to muscle dys-
function (Barca et al., 2016; Horvath et al., 2012). mtDNA maintenance
requires a pool of nuclear-encoded proteins whose dysfunction has
been associated with several human diseases. Notably, autosomal
recessive mutations in genes encoding the mtDNA polymerase POLG
and the mitochondrial helicase Twinkle result in two ataxic syndromes,
namely MIRAS (Winterthun et al., 2005) and infantile-onset SCA
IOSCA (Nikali et al., 2005), respectively. Mutated patients only show
minimal amount of mtDNA deletions and lack of mitochondrial myopa-
thy, suggesting that defects in ubiquitous proteins of mtDNA replica-
tive machinery can produce CNS-restricted degeneration.
Recently, Sanchez et al. (2016) also quantified the levels of mtDNA
in cerebellum of SCA1 mice, but they found no significant change in
mtDNA copy levels compared with control mice. Their experiments,
however, were performed on 5 weeks old mice, that is, in a very early
disease stage, and this may account for the divergence from our results.
The selective loss of specific neuronal subtypes is a central issue in
neurodegenerative disorders.
As PC dendrites branch more extensively than those of any other
neuron in the brain, they are probably more sensitive to reduced mito-
chondrial function. Gene expression analysis of mouse brain regions
showed high expression levels of genes involved in mitochondrial ATP
production (particularly those encoding COX subunits) in developing
cerebellum, when the majority of granule cells are engaged in axon
extension and synapse formation, and at a later stage (week 6) when
cerebellum has reached maturity (Matoba et al., 2000). More recently
Hosp et al. (2015) investigated the repertoire of proteins sequestered
by mutant ataxin-1 in the SCA1–82Q mouse model while the pro-
teome of PC cells in the Sca1(154Q/2Q) mice at a symptomatic stage
was assessed by mass spectrometry (Stucki et al., 2016). Although no
obvious factor involved in mtDNA maintenance were detected in these
datasets, prominent alterations in mitochondrial proteins were found.
Interestingly, mitochondrial morphology, found altered in affected PC
cells, relies upon a set of proteins, which are also involved in mtDNA
homeostasis (i.e., MFN2, OPA1, CHCHD10). It is noteworthy that
mutations in these proteins are also associated with neurodegenerative
disorders in human and models. For example, mitochondrial dysfunc-
tion has been previously reported in mouse PC lacking Mitofusin-2
(Mfn2), a factor involved in mitochondrial fusion pathway whose
impairment is associated in humans with an autosomal dominant form
of Charcot-Marie-Tooth disease (CMT2A) (Chen & Chan, 2009). The
authors documented the loss of mtDNA nucleoids in fusion-deficient
cells as the likely basis of reduced respiratory chain function. Interest-
ingly, loss of activity in electron transport chain complexes I and IV
seems to precede neuronal death.
Finally, Ito et al. (2015) demonstrated that the impairment of
mtDNA quality control due to loss of high-mobility group box 1
(HMGB1) protein is associated with the exacerbation of symptoms in
the Atxn1–154Q knock-in mice.
Although inherited ataxias are extremely heterogeneous, caused
by a variety of genes and gene mutations, and characterized by differ-
ent pathogenic mechanisms, oxidative stress seems to be a relevant
factor in the pathogenesis of SCA1 disease. Notably, mitochondrial
dysfunction likely contributes to the development of several other neu-
rodegenerative disorders, such as Huntington’s disease and amyotro-
phic lateral sclerosis (DiMauro, Hirano, & Schon, 2006). In addition,
previous studies showed that other triplet-expanded proteins might
impair mitochondrial biogenesis leading to neurodegeneration (Cui
et al., 2006).
Our data suggest that the mtDNA-dependent COX defect in PC
from SCA1 mice is rather specific. Since we found no differences in the
density, distribution, and morphology of the mitochondrial network at
PC level, we hypothesize the existence of factor(s) involved only in
mtDNA homeostasis whose expression or activity is impaired by
mutant ataxin in PC.
A wide variety of therapies for SCA1 is being investigated to pre-
serve PCs and therefore delay disease onset and slow its progression.
Mouse models, particularly the 154Q/2Q mouse, provide a valuable
model of the disease. While stem cell therapies have currently reached
the clinical trial stage, recent progress in gene and protein delivery
appear to be equally promising for SCA1 treatment (Wagner, O’Con-
nor, Donsante, & Boulis, 2016). The mitochondria-targeted antioxidant
molecule MitoQ also ameliorated mitochondrial morphology and
restored the activities of the electron transport chain complexes in
SCA1 mice (Stucki et al., 2016).
Overall, our data show that the mtDNA content parallels the oxi-
dative dysfunction demonstrated by histochemical evidence of COX
deficiency in SCA1 mice cerebella and that the mitochondrial oxidative
defect occurs as early as 8 weeks of age.
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